Physician profile
Michael Xu
NPI 1093179616
$3,109.20
in general payments reported to CMS, 2019-2025
20 companies · $292 in 2025
The $292 reported for 2025 was more than what 83% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.41 · 2020: $241 · 2021: $442 · 2022: $743 · 2023: $546 · 2024: $766 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $572.01 | 2020-2024 | Xarelto |
| Pfizer INC. | $503.65 | 2019-2025 | |
| Inari Medical, INC. | $446.12 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $334.65 | 2022-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $213.63 | 2019-2023 | |
| Abbvie INC. | $213.47 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.82 | 2020-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $143.85 | 2020-2023 | Lokelma |
| Gilead Sciences, INC. | $123.73 | 2023-2024 | Veklury |
| Abbott Laboratories | $123.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.39 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $42.92 | 2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $22.29 | 2025 | |
| Allergan, INC. | $20.46 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.74 | 2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $18.57 | 2023 | Ankle Fracture System |
| Genzyme Corporation | $18.25 | 2020 | |
| Chiesi USA, INC. | $17.07 | 2023 | Cleviprex |
| Merck Sharp & Dohme LLC | $15.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.